Novo Nordisk terminates program on innovative insulin

Despite being proclaimed as innovative and non-traditional in 2020, Novo Nordisk has announced that development of insulin 965 has been discontinued.

Photo: Niels Hougaard/ERH

Novo Nordisk has many clinical programs underway. Some make it all the way, others don’t.

Insulin 965, which potentially had built-in positive effects against cardiovascular diseases, falls in the latter category, according to the Danish pharmaceutical firm’s latest quarterly report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs